JP4160121B2 - アンジオスタチン生成のための方法及び組成物 - Google Patents

アンジオスタチン生成のための方法及び組成物 Download PDF

Info

Publication number
JP4160121B2
JP4160121B2 JP51753898A JP51753898A JP4160121B2 JP 4160121 B2 JP4160121 B2 JP 4160121B2 JP 51753898 A JP51753898 A JP 51753898A JP 51753898 A JP51753898 A JP 51753898A JP 4160121 B2 JP4160121 B2 JP 4160121B2
Authority
JP
Japan
Prior art keywords
plasminogen
angiostatin
plasmin
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51753898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001502534A5 (enExample
JP2001502534A (ja
Inventor
ソフ、ジェラルド
ティ． ゲイトリー、ステファン
トワルドウスキィ、プルゼミィスロウ
Original Assignee
ノースウエスタン ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウエスタン ユニバーシティー filed Critical ノースウエスタン ユニバーシティー
Publication of JP2001502534A publication Critical patent/JP2001502534A/ja
Publication of JP2001502534A5 publication Critical patent/JP2001502534A5/ja
Application granted granted Critical
Publication of JP4160121B2 publication Critical patent/JP4160121B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP51753898A 1996-09-17 1997-09-17 アンジオスタチン生成のための方法及び組成物 Expired - Fee Related JP4160121B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/710,305 1996-09-17
US08/710,305 US5801012A (en) 1996-09-17 1996-09-17 Methods and compositions for generating angiostatin
PCT/US1997/016539 WO1998015574A1 (en) 1996-09-17 1997-09-17 Methods and compositions for generating angiostatin

Publications (3)

Publication Number Publication Date
JP2001502534A JP2001502534A (ja) 2001-02-27
JP2001502534A5 JP2001502534A5 (enExample) 2005-05-12
JP4160121B2 true JP4160121B2 (ja) 2008-10-01

Family

ID=24853480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51753898A Expired - Fee Related JP4160121B2 (ja) 1996-09-17 1997-09-17 アンジオスタチン生成のための方法及び組成物

Country Status (9)

Country Link
US (2) US5801012A (enExample)
EP (2) EP0964869B1 (enExample)
JP (1) JP4160121B2 (enExample)
AT (1) ATE329926T1 (enExample)
AU (1) AU4422797A (enExample)
CA (1) CA2265550A1 (enExample)
DE (1) DE69736129T2 (enExample)
ES (1) ES2267151T3 (enExample)
WO (1) WO1998015574A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
EP1001985A1 (en) * 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
AU1731300A (en) * 1998-11-25 2000-06-13 Bristol-Myers Squibb Company Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
CA2384929C (en) 1999-09-15 2006-12-05 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
WO2001058921A2 (en) * 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
DE60134885D1 (de) 2000-11-28 2008-08-28 David M Waisman Antiangiogene polypeptide
ITMI20011995A1 (it) * 2001-09-26 2003-03-26 Ist Naz Ricerca Sul Cancro Sostanze ad attivita' antinfiammatoria
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
CA2514873C (en) * 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
US7090654B2 (en) * 2003-03-28 2006-08-15 Sherwood Services Ag Catheter with occlusion resistant tip
US7141035B2 (en) * 2003-03-28 2006-11-28 Sherwood Services Ag Catheter with occlusion resistant tip
US7776005B2 (en) * 2003-03-28 2010-08-17 Covidien Ag Triple lumen catheter with occlusion resistant tip
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
CN1889929B (zh) * 2003-11-14 2013-04-10 阿尔萨公司 药物递送媒介物中的赋形剂
KR20070106979A (ko) * 2004-11-04 2007-11-06 코비디엔 아게 카테터 삽입 장치
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2009100617A1 (zh) * 2008-02-04 2009-08-20 Shanghai First People's Hospital 抑制血管新生的多肽及其应用
US8187231B2 (en) * 2009-06-26 2012-05-29 Tyco Healthcare Group Lp Catheterization system
CA2715857A1 (en) 2009-09-30 2011-03-30 Tyco Healthcare Group Lp Medical catheter having a design providing low recirculation and reversibility
US9072867B2 (en) 2011-09-30 2015-07-07 Covidien Lp Catheter with external flow channel
US8747343B2 (en) 2011-09-30 2014-06-10 Covidien Lp Hemodialysis catheter with improved side opening design
US9216163B2 (en) 2013-05-20 2015-12-22 Kyorin Pharmaceutical Co., Ltd. Method of inhibiting angiogenesis
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431342C3 (de) * 1973-07-27 1978-10-26 Behringwerke Ag, 3550 Marburg Verfahren zur Messung des Plasminogengehaltes durch Bestimmung der Bildung von Fibrin in einer Probe
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
EP0359036B1 (en) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
MX9708217A (es) 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
AU6264596A (en) 1995-06-07 1996-12-30 Children's Medical Center Corporation Diagnosis, prognosis and monitoring of angiogenesis dependen t diseases
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
EP0857210B1 (en) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
ES2217340T3 (es) 1995-12-13 2004-11-01 The Children's Medical Center Corporation Inhibidor de la proliferacion de celulas endoteliales y utilizacion de este.
JP4426650B2 (ja) 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo

Also Published As

Publication number Publication date
EP0964869B1 (en) 2006-06-14
EP0964869A4 (en) 2003-06-04
WO1998015574A1 (en) 1998-04-16
JP2001502534A (ja) 2001-02-27
CA2265550A1 (en) 1998-04-16
DE69736129D1 (de) 2006-07-27
ES2267151T3 (es) 2007-03-01
EP0964869A1 (en) 1999-12-22
US6576609B1 (en) 2003-06-10
EP1705184A1 (en) 2006-09-27
US5801012A (en) 1998-09-01
DE69736129T2 (de) 2007-01-04
ATE329926T1 (de) 2006-07-15
AU4422797A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
EP0964869B1 (en) Methods and compositions for the treatment of neoplastic diseases
JP4426650B2 (ja) 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
US5801146A (en) Compound and method for inhibiting angiogenesis
JP3787157B2 (ja) アンジオスタチンフラグメント、アンジオスタチン凝集体および使用方法
JPH09512173A (ja) アンジオスタチンおよび血管形成の抑制におけるその使用
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
JP2002510209A (ja) インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
JP2002502359A (ja) 内皮細胞増殖阻害剤およびその使用法
US5861298A (en) Cathepsin K gene
JP2851287B2 (ja) 酵素前駆体型ヒトプロテインｃの発現のためのベクターおよび化合物
WO2001058921A9 (en) Methods and compositions for generating angiostatin
US5939284A (en) Protein phosphatase 1 binding protein, R5
JP2002516261A (ja) セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
US20060099671A1 (en) Methods and compositions for generating angiostatin
JP2002535372A (ja) プラスミノーゲンクリングル４領域フラグメントおよび利用法
JP2004508048A (ja) 内皮細胞増殖阻害物質に関する材料と方法
JP4666767B2 (ja) プラスミノーゲンの脱グリコシル化クリングル１〜５領域フラグメント及びこれらの使用方法
WO2000049871A1 (en) An anti-angiogenic kringle protein and its mutants
JP2001505870A (ja) プロタンパク質変換酵素
KR100506571B1 (ko) 플라스미노겐으로부터유래된맥관형성억제펩타이드
HK1070279A (en) Endothelial cell proliferation inhibitor and method of use
HK1002457B (en) Angiostatin fragments and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080617

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080717

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110725

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees